Fitzsimon_menu

Find out what's happening on campus and across the industry.

Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.

Fitzsimons Innovation Community Wins CSBA Building Momentum Award
News | Nov 29, 2022

Fitzsimons Innovation Community Wins CSBA Building Momentum Award

The award recognizes the investments Fitzsimons Innovation Community is making to advance Colorado’s life sciences community and better position the entire ecosystem for growth

Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials
News | Nov 09, 2022

Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials

Congresswoman Diana DeGette (D-CO) visits the Gates Biomanufacturing Facility's Protein Suite, in which GMP-grade AV-1980R was manufactured for the Institute for Molecular Medicine's phase 1 clinical...

Atara Biotherapeutics was recently featured on Tomorrow's World Today's episode "Healing Heroes"
News | Oct 25, 2022

Atara Biotherapeutics was recently featured on Tomorrow's World Today's episode "Healing Heroes"

Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.

Bioengineering Lab Advances New Approaches to Congenital Heart Surgery
News | Oct 25, 2022

Bioengineering Lab Advances New Approaches to Congenital Heart Surgery

Rather than just redirecting flow, implantations provide therapy to heart cells and drive new tissue

Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers
News | Oct 25, 2022

Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers

Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).

University of Colorado faculty attract $1.46 billion in sponsored research funding and gifts
News | Oct 25, 2022

University of Colorado faculty attract $1.46 billion in sponsored research funding and gifts

University of Colorado faculty this year attracted $1.46 billion in sponsored research funding and gifts supporting research. The support powers wide-ranging discovery and impact, ultimately benefiting Colorado, the nation and the world.

Foresight Diagnostics Patent Issued for Minimal Residual Disease Detection Technology   Foresight_Diagnostics
News | Oct 25, 2022

Foresight Diagnostics Patent Issued for Minimal Residual Disease Detection Technology  

Foresight Diagnostics, Inc, a leader in cancer diagnostics and cancer relapse testing, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company patent No. 11,447,833 for the detection of minimal residual disease (MRD) using its personalized phased variant detection platform. "We are pleased that the USPTO has recognized the novel nature of our proprietary technology and are excited about the impact we believe this technology will have on the lives of cancer patients," said Dr. Jake Chabon, Ph.D., Chief Executive Officer of Foresight Diagnostics.

Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen
News | Oct 25, 2022

Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen

"Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation"

CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
News | Oct 17, 2022

CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics and their partner Pierre Fabre Group announce that the European Medicines Agency's CHMP issued a positive opinion for their investigational therapy to treat adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.

Fitzsimons Innovation Community Growing as Life Sciences Hub in Aurora
News | Jun 24, 2022

Fitzsimons Innovation Community Growing as Life Sciences Hub in Aurora

The plan calls for 45 thousand jobs at full buildout. Already there is a $10 Billion dollar annual economic impact in a single square mile....

The Next Generation of Digitally Enabled Healthcare Innovations
Blog | May 31, 2022

The Next Generation of Digitally Enabled Healthcare Innovations

As the main gateway to a large research and clinical infrastructure, CU Innovations pairs industry partners with clinicians to create next-generation products that can ultimately reach patient care. Thanks to hospital partners at Children’s Hospital Colorado and the UCHealth system, CU Innovations has established a living clinical laboratory for testing and validating the best healthcare technologies.

US-Based Biotechnology Company, Taiga Launches Breakthrough Veterinary Cancer Treatment in Singapore
News | Apr 29, 2022

US-Based Biotechnology Company, Taiga Launches Breakthrough Veterinary Cancer Treatment in Singapore

Taiga Biotechnologies, a clinical-stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease...